An observational study in Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer and Stage IIIC Ovarian Cancer, sponsored by Gynecologic Oncology Group. Recruiting at 1 site in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2017-05-05.
Sponsored by Gynecologic Oncology Group · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in Ovarian Neoplasms by Gynecologic Oncology Group — 1 open to participants now, 1 under way, none of them phase 3. Ovarian Neoplasms · Gynecologic Oncology Group.
Among the 75 studies in Ovarian Neoplasms by Gynecologic Oncology Group, this one is the 7th largest by planned enrollment of the 11 observational ones that give a count, is one of 4 that started in 2004, is one of 12 observational ones, and was the 62nd registered.
3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.
Browse Ovarian Neoplasms studies →1 of the 75 studies in Ovarian Neoplasms by Gynecologic Oncology Group is open now, in 1 country.
By country, each count listing its studies:
Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
First in 1992; this study’s year is marked. 4 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 174 is below the median of 200 across 617 observational studies indexed under Ovarian Neoplasms.
Median enrollment 32 across the 42 interventional studies, 247 across the 11 observational. Of the 62 that completed or were terminated, 17 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
Gynecologic Oncology Group is the lead sponsor of 188 studies on the registry; 1 is open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 75 studies in Ovarian Neoplasms by Gynecologic Oncology Group, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This research study is looking at tumor tissue samples from patients who have undergone surgery for advanced stage III or stage IV ovarian epithelial cancer. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn how tumor infiltrating T cells can predict how patients will respond to treatment.
PRIMARY OBJECTIVES:
I. To validate the ability of intratumoral tumor-infiltrating T lymphocytes (TILs) to predict progression-free survival (PFS) in patients with suboptimally debulked advanced stage III or IV ovarian epithelial cancer.
II. To validate the ability of intratumoral TILs to predict PFS in patients with optimally debulked disease.
SECONDARY OBJECTIVES:
I. To validate the ability of intratumoral TILs to predict overall survival of patients with suboptimally debulked disease.
II. To validate the ability of intratumoral TILs to predict overall survival of patients with optimally debulked disease.
OUTLINE:
Patients are stratified according to status of debulked disease (suboptimal vs optimal).
Previously collected tumor tissue samples are analyzed for tumor-infiltrating lymphocytes (TIL) via immunohistochemistry and double immunofluorescence assays using standard immunostaining.
Inclusion Criteria:
Must have fixed and paraffin-embedded tissue from primary surgery available from 1 of the following sources:
Previously collected tumor tissue samples are analyzed for TIL via immunohistochemistry and double immunofluorescence assays using standard immunostaining.
Other: Laboratory Biomarker Analysis
Samples are analyzed in laboratory studies
Overall survival curves
The Kaplan-Meier method will be used to estimate the survival curves, and the log-rank test will be used to test the difference between survival curves for TIL positive and negative patients. All of the tests will be two-sided and the significant levels will be set a 0.05.
Time frame: Baseline
Progression-free survival curves
The Kaplan-Meier method will be used to estimate the survival curves, and the log-rank test will be used to test the difference between survival curves for TIL positive and negative patients. All of the tests will be two-sided and the significant levels will be set a 0.05.
Time frame: Baseline
The record gives a start of Sep 2004 and a primary completion of Jan 2100. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.